

Prior Authorization Request Form for
benralizumab pen (**Fasenra**)



JOHNS HOPKINS
HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider	
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

**FAX Completed Form and
Applicable Progress Notes to:
(410) 424-4037**

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step 1 Please complete patient and physician information (please print):

1 Patient Name: _____ Physician Name: _____
 Address: _____ Address: _____
 Sponsor ID # _____ Phone #: _____
 Date of Birth: _____ Secure Fax #: _____

Step 2 Please complete the clinical assessment:

2 1. Does the patient have a diagnosis of severe persistent eosinophilic asthma?	<input type="checkbox"/> Yes Proceed to question 2	<input type="checkbox"/> No STOP Coverage not approved
2. Is the patient 12 years old or older?	<input type="checkbox"/> Yes Proceed to question 3	<input type="checkbox"/> No STOP Coverage not approved
3. Is the medication being prescribed by or in consultation with an allergist, immunologist, or pulmonologist?	<input type="checkbox"/> Yes Proceed to question 4	<input type="checkbox"/> No STOP Coverage not approved
4. Does the patient have an eosinophilic phenotype asthma as defined as either: <ul style="list-style-type: none"> blood eosinophil count of GREATER than 150 cells/mcL within the past month while on oral corticosteroids or Greater than or Equal to 300 cell/mcL within the past year? 	<input type="checkbox"/> Yes Proceed to question 5	<input type="checkbox"/> No STOP Coverage not approved
5. Has the patient's asthma been uncontrolled despite adherence to optimized medication therapy regimen? Uncontrolled asthma is defined as: <ul style="list-style-type: none"> hospitalization for asthma in the past year, requiring a course of oral corticosteroids twice in the past year, or daily high-dose inhaled corticosteroid (ICS) with inability to taper off the ICS. 	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No STOP Coverage not approved

<p>6. Has the patient tried and failed an adequate course (3 months) of at least two of the following while using a high-dose inhaled corticosteroid:</p> <ul style="list-style-type: none"> • long-acting beta-agonist (LABA), (for example, Serevent Diskus, Advair Diskus/HFA, AirDuo RespiClick, Symbicort, etc.), • long acting muscarinic antagonist (LAMA), (for example Spiriva Respimat) OR • leukotriene receptor antagonist (for example montelukast, Singulair) 	<p><input type="checkbox"/> Yes Sign and date below</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
---	---	--

Step 3 I certify the above is true to the best of my knowledge. Please sign and date:

3

_____ Prescriber Signature

_____ Date

[13 December 2019]

For Internal Use Only	
<input type="checkbox"/> Approved:	Duration of Approval: ____month(s)
<input type="checkbox"/> Denied:	Authorized By:
<input type="checkbox"/> Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: